Redefining Treatment Success and Patient Preference in PsO

Historically, psoriasis treatments followed a relatively clear divide. Traditional oral systemic and immunosuppressant agents such as methotrexate, cyclosporine, and acitretin have helped countless patients, but their risk-benefit profiles frequently complicate long-term management or result in decreased adherence. Meanwhile, targeted, injectable biologic therapies have been refined through clinical research, delivering increasingly effective disease control with minimal safety concerns.

For years, the practical differences between oral and biologic therapies strongly shaped treatment decisions, as oral therapy often meant accepting either lower efficacy or a higher potential for adverse events. Although apremilast marked an important shift toward a safer oral option, it was largely overshadowed by the clinical efficacy and safety profile of subsequent biologics targeting IL-17 and IL-23. As a result, clinicians largely viewed biologics as the preferred therapeutic option, even when that preference conflicted with many patients’ desire for an oral treatment. 

That gap is now closing with the recent approval of an oral small peptide inhibitor of the IL-23 receptor and emerging next-generation small molecules targeting TYK2. These novel treatments are beginning to reshape shared decision-making, redefine oral treatment expectations, and reduce the efficacy gap between oral and injectable therapies.

Innovation is also continuing among biologic therapies. Investigational biologic therapies are not only delivering better skin control but also offering simultaneous inhibition of several psoriasis-related immune pathways as well as improved control of joint disease. Research efforts are also focused on establishing more comprehensive treatment strategies and lowering the overall treatment burden with fewer injections needed to achieve skin clearance through extended half-life technologies. Therapies that maintain or improve efficacy while reducing injection frequency have the potential to enhance treatment satisfaction, improve adherence, and may even reduce overall healthcare costs.

These developments reflect a growing emphasis on patient-centered care and long-term disease control. Though psoriasis may be one of the best-treated inflammatory diseases, our work is far from complete. Continued innovation is essential if we are to address remaining unmet needs and eventually achieve durable disease remission.